SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

UroGen Pharma Q3 Results Due November 4

UroGen Pharma is scheduled to report before the market opens. Analysts estimate revenue at 89.92 million USD and EPS at 0.11 USD.

URGN

Related stories